XBIOTECH INC. Increase (Decrease) in Accounts Receivable
XBIOTECH INC. (XBIT) reported Increase (Decrease) in Accounts Receivable of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2023-11-09
- XBIOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- XBIOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2022-12-31 was -$1.53M.
- XBIOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2022-09-30 was $1.53M, a 7952.63% increase year-over-year.
- XBIOTECH INC. increase (decrease) in accounts receivable for the quarter ending 2022-06-30 was -$500.00K.
- XBIOTECH INC. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
- XBIOTECH INC. increase (decrease) in accounts receivable for fiscal 2021 was -$4.11M, a 200.00% decline from fiscal 2020.
- XBIOTECH INC. increase (decrease) in accounts receivable for fiscal 2020 was $4.11M.
- XBIOTECH INC. increase (decrease) in accounts receivable for fiscal 2019 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | -$1.53M derived: sum of 2 quarters · filed 2023-05-10 | $0.00 derived: sum of 3 quarters · filed 2023-11-09 | -$500.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | -$500.00K derived: sum of 3 quarters · filed 2023-11-09 | $0.00 10-K · filed 2023-03-15 |
| 2022-09-30 | $1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.03M derived: sum of 2 quarters · filed 2023-11-09 | $1.53M 10-Q · filed 2023-11-09 | $1.49M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | -$44.00K derived: sum of 3 quarters · filed 2023-05-10 | -$25.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-10 | $456.00K derived: sum of 2 quarters · filed 2023-05-10 | $475.00K derived: sum of 3 quarters · filed 2023-05-10 | -$1.19M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$25.00K derived: sum of 2 quarters · filed 2023-03-15 | -$1.69M derived: sum of 3 quarters · filed 2023-03-15 | -$4.11M 10-K · filed 2023-03-15 |
| 2021-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.64M derived: sum of 2 quarters · filed 2022-11-09 | -$4.07M 10-Q · filed 2022-11-09 | -$6.02M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$4.09M 10-Q · filed 2022-08-10 | -$6.04M derived: sum of 3 quarters · filed 2022-08-10 | -$20.65M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$2.42M 10-Q · filed 2022-05-10 | -$4.37M derived: sum of 2 quarters · filed 2022-05-10 | -$18.99M derived: sum of 3 quarters · filed 2022-05-10 | -$7.99M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$16.57M derived: sum of 2 quarters · filed 2022-03-15 | -$5.57M derived: sum of 3 quarters · filed 2022-03-15 | $4.11M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$14.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$3.62M derived: sum of 2 quarters · filed 2021-11-09 | $6.06M 10-Q · filed 2021-11-09 | $6.06M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $20.68M 10-Q · filed 2021-08-09 | $20.68M derived: sum of 3 quarters · filed 2022-03-15 | $20.68M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $9.68M 10-Q · filed 2021-05-10 | $9.68M derived: sum of 2 quarters · filed 2022-03-15 | $9.68M derived: sum of 3 quarters · filed 2022-03-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |